Bare-metal Stent vs Covered Stent in Chinese Patients With Subclavian Occlusive Lesions
NCT ID: NCT03737162
Last Updated: 2018-11-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
408 participants
INTERVENTIONAL
2018-04-02
2020-07-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Metal Bare Stent With 125 Iodine （125I）Seeds for the Treatment of Malignant Central Airway Stenosis
NCT03944408
Airway Segmented Stent Modified With 3D Printing for Malignant Stricture Involving Carina and Distal Bronchi
NCT03890575
Brachial Versus Femoral Access for Carotid Artery Stenting
NCT06557135
Dissection of the Superior Mesenteric Artery
NCT05171842
Radiation Stent Versus Self-expanding Metallic Stents (SEMS) for Palliative Treatment of Malignant Biliary Stricture
NCT01320241
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Covered stent group
Covered stent
Stent implantation of subclavian artery
Stent implantation of subclavian artery
Bare-metal stent group
Bare-metal stent
Stent implantation of subclavian artery
Stent implantation of subclavian artery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Stent implantation of subclavian artery
Stent implantation of subclavian artery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Left subclavian artery disease；
3. The cause of clinical considerations is arteriosclerosis ；
4. The presence of target organ ischemic symptoms, ie dizziness, headache, transient ischemic attack (TIA), stroke, or other related neurological symptoms caused by ischemia of the vertebral artery in the past 6 months, or the presence of arterial stenosis beyond the upper extremity limb ischemia symptoms subclavian；
5. The patient understands the trial objective, understands and accepts the duration of the study，is able and willing to comply with all requirements，including follow-up and evaluation of it, voluntarily participates in the study and signs Informed Consent Form.
Anatomy Criteria
6. Subclavian artery independent disease（Do not merge carotid or vertebral artery disease ）；
7. Subclavian artery satisfies one of the following criteria：
1. a) Ultrasonography suggests stenosis ≥ 70%，or CT ANGIOGRAM / angiography showed stenosis ≥ 70%；
2. Iconography examination confirmed vertebral artery steals；
3. Length of lesion is not involved in vertebral artery opening；
4. Lesions in subclavian artery the beginning portion；
8. The stent can reach the site of lesion smoothly as expected.
Exclusion Criteria
2. Serious ipsilateral stroke occurred in the past and may confuse the judgment of the study endpoint ；
3. Patients with severe dementia ；
4. Patients with spontaneous intracerebral hemorrhage in the past 12 months ；
5. Patients stroke episodes recently， CT or MRI suggested that the lesion is large，and may be with the risk of hemorrhagic transformation ；
6. Large size of cerebral infarction or myocardial infarction occurred within 30 days ；
7. Patients with large intracranial aneurysms (diameter\> 5mm)，and cannot be treated in advance or contemporaneous ；
8. Chronic total occlusion without obvious cerebral ischemia symptoms ；
9. Patients with hemorrhagic transformation of cerebral arterial thrombosis within 60 days before surgery ；
10. Hemoglobin \<100 g/l， Platelet count \<125×109/L， INR\>1.5， Bleeding time \> 1 min，patients with exceeding the upper limits of normal，or heparin-related thrombocytopenia ；
11. Patients unable to perform normal angiographic evaluation or unsafe percutaneous puncture poin；
12. Patients with neurologic disorder that caused transient or permanent neurological deficits within 2 years before the surgery and can not be identified with TIA or stroke ；
13. Patients with other cardiac emboli sources, such as left ventricular aneurysm, intraluminal filling defect, cardiomyopathy, aortic or mitral prosthetic heart valve, calcific aortic stenosis, infective endocarditis, mitral stenosis, atrial septal defect, atrial septal aneurysm, or left atrial myxoma；
14. Surgical contraindications or patients with high risk of surgery defined as having any of the following；It is known that two or more proximal or main coronary artery stenosis ≥70%, untreated or unable to pass；Ejection fraction \<30% or New York Heart Association (NYHA) functional class III or higher；Unstable angina，ie angina at resting state and electrocardiogram changes；Currently waiting main organ transplants (ie heart, lung, liver, kidney), or are doing relevant evaluate；Malignant tumor or respiratory insufficiency, life expectancy \< 5 years or FORCED EXPIRATORY VOLUME AT ONE SECOND \< 30% (predicted)；Dialysis-dependent renal failure； Need to perform other general anesthesia during the same period ；
15. There may be one or more anatomical conditions affecting the normal operative approach in patients； there may be one or more anatomic situations to increase the risk of adverse events in patients with high operative risk；including： Neck radiation therapy history； Radical neck surgery history；Subclavian artery dissection；Lesions series；Severe long segment calcification of the subclavian artery and severe stenosis or occlusion of the basilar artery；Inaccessible lesions by endoluminal methods (Severe distortion of the aortic arch branch, no suitable introduction of arteries, aortic arch anatomy special）；
16. Investigators consider the patient inappropriate to participate in this clinical trial；
17. Those who participated in clinical trials of other drugs or medical devices before the inclusion did not reach the end of the time limit.
18. Rheumatic immune diseases, such as Takayasu arteritis.
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University First Hospital
OTHER
The First Affiliated Hospital of Dalian Medical University
OTHER
Shanghai Zhongshan Hospital
OTHER
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
Shanghai Changzheng Hospital
OTHER
First Affiliated Hospital Xi'an Jiaotong University
OTHER
Xuanwu Hospital, Beijing
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yong-Quan Gu
Prof.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
YongQuan Gu YQ Gu, Prof.
Role: PRINCIPAL_INVESTIGATOR
Xuanwu Hospital, Beijing
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking hospital first University
Beijing, , China
The first affiliated Hospital of Dalian Medical University
Dalian, , China
Shanghai Changhai Hospital
Shanghai, , China
Shanghai Changzheng Hospital
Shanghai, , China
Zhongshan Hospital affiliated to Fudan University
Shanghai, , China
The first affiliated Hospital of Xi ' an Jiaotong University
Xi'an, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
YingHua Zou YH Zou, Prof.
Role: primary
Feng Wang F Wang, Prof.
Role: primary
ZhiQing Zhao ZQ Zhao, Prof.
Role: primary
LeFeng Qu LF Qu, Prof.
Role: primary
DaQiao Guo DQ Guo, Prof.
Role: primary
JianLin Liu JL Liu, Prof.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
china subclavian
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.